Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000
Debt
Debt-to-Equity Ratio0.32
Current Ratio7.07
Quick Ratio7.07
Price-To-Earnings
Trailing P/E Ratio-3.40
Forward P/E Ratio-4.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.37 million
Price / Sales35.88
Cash FlowN/A
Price / CashN/A
Book Value$2.04 per share
Price / Book4.34
Profitability
EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net MarginsN/A
Return on Equity-99.50%
Return on Assets-42.59%
Miscellaneous
Employees137
Outstanding Shares54,200,000
Market Cap$482.36
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics (NASDAQ:CYTK) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company earned $5.27 million during the quarter, compared to analysts' expectations of $5.50 million. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
8 analysts have issued 12-month price targets for Cytokinetics' stock. Their predictions range from $10.00 to $24.00. On average, they expect Cytokinetics' stock price to reach $15.6250 in the next year. This suggests a possible upside of 76.6% from the stock's current price. View Analyst Ratings for Cytokinetics.
What is the consensus analysts' recommendation for Cytokinetics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (7/17/2018)
- 2. Cantor Fitzgerald analysts commented, "Reldesemtiv and omecamtiv mecarbil, CYTK’s lead programs, have sizable opportunities given the limited treatment options in the markets that are being explored but are novel mechanisms, which enhances the risk profile, in our view. The loss of tirasemtiv was a sizable blow to CYTK and new data for reldesemtiv are a plus, in our view, with the shares now essentially at our price target." (6/17/2018)
- 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), TherapeuticsMD (TXMD) and Mirati Therapeutics (MRTX).
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)
Has Cytokinetics been receiving favorable news coverage?
Media coverage about CYTK stock has been trending somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytokinetics earned a daily sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.32 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fox Run Management L.L.C. (0.06%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.
Which major investors are buying Cytokinetics stock?
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $8.85.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $482.36 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
